Scarica l'app Stockscreener
59.46
0.15%
-0.09
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$59.55
Aprire:
$59.97
Volume 24 ore:
6.49M
Relative Volume:
0.57
Capitalizzazione di mercato:
$121.42B
Reddito:
$48.48B
Utile/perdita netta:
$7.27B
Rapporto P/E:
16.69
EPS:
3.5626
Flusso di cassa netto:
$11.91B
1 W Prestazione:
+4.32%
1M Prestazione:
+1.12%
6M Prestazione:
+28.56%
1 anno Prestazione:
+26.43%
Intervallo 1D:
$59.25
$60.25
Intervallo di 1 settimana:
$57.08
$60.25
Portata 52W:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Nome
Bristol Myers Squibb Co
Settore
Industria
Telefono
(609) 252-4621
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, AZN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
59.46 | 121.61B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,065.00 | 928.88B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.34 | 557.82B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
215.70 | 378.98B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
122.41 | 286.20B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.03 | 294.27B | 60.48B | 10.40B | 8.05B | 3.3297 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-12-12 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Iniziato | Piper Sandler | Overweight |
| 2024-12-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-13 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-07-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
| 2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-07-10 | Iniziato | SVB Securities | Market Perform |
| 2023-06-28 | Iniziato | Daiwa Securities | Outperform |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Iniziato | Credit Suisse | Neutral |
| 2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Underweight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-01 | Downgrade | Argus | Buy → Hold |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Aggiornamento | Truist | Hold → Buy |
| 2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-07-28 | Iniziato | Raymond James | Outperform |
| 2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-06 | Ripresa | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | Argus | Hold → Buy |
| 2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-05-20 | Downgrade | Argus | Buy → Hold |
| 2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Ripresa | JP Morgan | Overweight |
| 2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
| 2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Meiji Yasuda Asset Management Co Ltd. Purchases 55,355 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Tempus AI, Inc. (TEM) and Bristol Myers Announce a Strategic Partnership - Insider Monkey
Bristol-Myers Squibb Company stock (US0897961004): Analyst moves and dividend draw fresh attention - AD HOC NEWS
BioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung - GlobeNewswire Inc.
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline - BioSpace
HALL CAPITAL MANAGEMENT CO INC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
ETFs Investing in Bristol-Myers Squibb Company Stocks - TradingView
In Alzheimer’s, Bristol Myers sees big promise beyond amyloid - BioPharma Dive
Bristol Myers Squibb Partners With Anthropic to Deploy Claude Across Global Operations - Digital Health News
Why so many pharmaceutical giants want to invest billions in Houston - The Business Journals
BMS expands AI push with Anthropic partnership - The Pharma Letter
PNC Financial Services Group Inc. Sells 225,894 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Hengrui, BMS deal watershed moment for China biotech - BioWorld News
Biopharma Giant Bristol Myers Squibb Partners with Anthropic for AI Integration - GuruFocus
Anthropic And OpenAI--Building Different Competitive Advantages - Benzinga
Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery - Benzinga
Bristol Myers deepens AI investment with Anthropic deal - BioPharma Dive
Anthropic signs enterprise AI deal with Bristol Myers Squibb - MobiHealthNews
BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows - Fierce Pharma
Bristol Myers Squibb Expands AI Push With Anthropic’s Claude for 30,000 Employees - citybiz
Bristol Myers to deploy Anthropic’s Claude AI model to accelerate drug discovery - The News International
Exclusive | Bristol-Myers Squibb Brings Anthropic’s Claude to 30,000 of Its Staff - WSJ
Bristol-Myers Squibb (BMY) Gets a Hold from Scotiabank - The Globe and Mail
Bristol Myers to deploy Anthropic’s Claude AI model to speed up drug discovery By Reuters - Investing.com
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery - Reuters
Bristol Myers Squibb partners with Anthropic to deploy Claude AI By Investing.com - Investing.com Canada
Bristol Myers, Anthropic to partner on Claude use - Breakingthenews.net
How Bristol Myers will use Anthropic’s Claude to speed medicines to patients - Stock Titan
BMY Technical Analysis | Trend, Signals & Chart Patterns | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
TiNivo-2 Completion: What Bristol-Myers Squibb’s Kidney Cancer Trial Means for Investors - TipRanks
Bristol-Myers Squibb Company stock (US0897961004): oncology pipeline and US expansion keep the pharm - AD HOC NEWS
Pharma giant considers Houston for $1B manufacturing campus - InnovationMap
Resona Asset Management Co. Ltd. Sells 21,761 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Supreme Court Hands Major Blow To Big Pharma's Fight Against Biden-Era Medicare Drug Pricing Law - Benzinga
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts - Yahoo Finance
Bristol Myers Squibb eyes $1B drug manufacturing campus in Generation Park - Community Impact | News
SCOTUS rejects Medicare drug price negotiation appeals by drugmakers - Modern Healthcare
Bristol-Myers Squibb Company stock (US0897961004): cancer drug news and pipeline focus after earning - AD HOC NEWS
Bristol-Myers Squibb Made Its Pipeline Case at BofA. Now Comes the Proof. - TIKR.com
BMY: Bristol Myers Squibb and Hengrui Pharma Strike $15.2B Licen - GuruFocus
Pharmaceutical giant eyes Houston for $1 billion campus - Chron
MCDONALD PARTNERS LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Vestcor Inc's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Another pharma giant eyes Houston for $1B plant with hundreds of jobs possible - KHOU
Bristol Myers Squibb eyes Houston for $1B pharmaceutical plant - The Business Journals
Biopharma Collaboration: Bristol Myers Squibb Partners with Heng - GuruFocus
Bristol Myers Squibb touts pipeline gains as shareholders back board at annual meeting - MSN
Bristol Myers Squibb partners with Hengrui Pharma to develop and test drugs early in China. - Pluang
Bristol Myers Squibb Partners with Hengrui Pharma for Drug Development - Intellectia AI
Bristol Myers Squibb and Hengrui Forge $15.2 Billion Strategic Alliance, Reshaping China-Out Licensing Landscape - Oncodaily
Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.19%
2.96%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):